<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3853">
  <stage>Registered</stage>
  <submitdate>6/12/2012</submitdate>
  <approvaldate>6/12/2012</approvaldate>
  <nctid>NCT01745367</nctid>
  <trial_identification>
    <studytitle>Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer</studytitle>
    <scientifictitle>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-center Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym>BATON-BC</trialacronym>
    <secondaryid>2012-003507-35</secondaryid>
    <secondaryid>AV-951-12-204</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Triple Negative Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tivozanib Hydrochloride
Treatment: drugs - paclitaxel

Active Comparator: Placebo in combination with paclitaxel - Placebo orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).

Experimental: Tivozanib Hydrochloride in combination with paclitaxel - 1.5 mg tivozanib hydrochloride orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).


Treatment: drugs: Tivozanib Hydrochloride


Treatment: drugs: paclitaxel


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival</outcome>
      <timepoint>approximately 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate</outcome>
      <timepoint>approximately 48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response</outcome>
      <timepoint>approximately 48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>approximately 48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects with AEs and SAEs</outcome>
      <timepoint>approximately 48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK profile of tivozanib hydrochloride in combination with paclitaxel.</outcome>
      <timepoint>Cycle 1, Day 1, Day 8, Day 15 and Cycle 2, Day 1, pre- and post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gene signature for potential predictiveness of response to treatment with tivozanib hydrochloride</outcome>
      <timepoint>Baseline (approximately 2 cycles)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Locally recurrent or metastatic TNBC, defined as ER/PR &lt;1%, HER2 0-1+, or 2+ with
             negative FISH

          -  Measurable disease per RECIST version 1.1

          -  ECOG performance status of 0 or 1

          -  Confirmed available archival tumor tissue.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  More than 1 prior systemic chemotherapy for treatment of locally recurrent or
             metastatic breast cancer (neoadjuvant and adjuvant therapy is allowed provided the
             subject did not progress within 12 months of taxane based therapy

          -  Prior treatment with VEGF pathway targeted agent

          -  Major surgery within 4 weeks or minor surgery or radiotherapy within 2 weeks of first
             dose of study drug

          -  Known history of central nervous system metastasis (subjects with previously treated
             (radiotherapy or surgery) brain metastasis that have been stable off steroids or
             enzyme-inducing antiepileptic drugs for at least 3 months following prior treatment
             may be enrolled)

          -  Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or
             coagulation disorders

          -  Significant serum chemistry or urinalysis abnormalities

          -  Significant cardiovascular disease, including: uncontrolled hypertension; myocardial
             infarction or unstable angina within 6 months prior to administration of first dose of
             study drug; and symptomatic left ventricular dysfunction or baseline left ventricular
             ejection fraction (LVEF) by multigated acquisition scan (MUGA) or ECHO.

          -  Severe peripheral neuropathy = Grade 2

          -  Currently active second primary malignancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>30</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital> - Port Macquarie</hospital>
    <hospital> - Woodville South</hospital>
    <hospital> - East Bentleigh</hospital>
    <hospital> - Newcastle, New South Wales</hospital>
    <hospital> - South Brisbane</hospital>
    <hospital> - St Leonards, New South Wales</hospital>
    <postcode> - Port Macquarie</postcode>
    <postcode> - Woodville South</postcode>
    <postcode> - East Bentleigh</postcode>
    <postcode> - Newcastle, New South Wales</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - St Leonards, New South Wales</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bahamas</country>
      <state>Nassau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>St. John's, NL</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hanau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Avellino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Viterbo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Donetsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Uzhhorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnytsia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AVEO Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Astellas Pharma Inc</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study
      for subjects with locally recurrent or metastatic triple negative breast cancer.

      Patients will be randomized 2:1 to either tivozanib hydrochloride and weekly paclitaxel or
      placebo and weekly paclitaxel.

      Subjects will be stratified based on Eastern Cooperative Oncology Group (ECOG) performance
      score (0 vs 1) and line of treatment (first vs second).

      All subjects will be evaluated for progression free survival and overall survival as well as
      safety and tolerability. Biomarker and pharmacokinetic (PK) analysis are also included in
      study. This study will determine whether tivozanib hydrocholoride combined with weekly
      paclitaxel improves clinical outcomes in patients with triple negative breast cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01745367</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>